Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06743776 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06743776 · ClinicalTrials.gov record · last posted 2026-08-18

Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

Name: Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS — clinical trial record (NCT06743776)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SEANOBI-ALS

StatusNo Longer Available

PhaseNot specified

SponsorMayo Clinic

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this Expanded Access Program is to provide MN-166 (ibudilast) to ALS patients who are not eligible for an enrolling ALS clinical trial. This Expanded Access Program will assess if MN-166 can help people with ALS in slowing down the progression of the disease.

Protocol amendment history 1 change detected by DataLookout

2026-08-19

Trial status changed: Available → No Longer Available

Trial Details

NCT Number	NCT06743776
Lead Sponsor	Mayo Clinic Collaborators: WideTrial, Inc., MediciNova, National Institute of Neurological Disorders and Stroke (NINDS)
Conditions	ALS
Updated on ClinicalTrials.gov	2026-08-18